LigoCyte Pharmaceuticals Raises $6.5M

Bozeman, Montana-based LigoCyte Pharaceuticals, a biotechnology firm focused on treatments for gastrointestinal and respiratory conditions, has raised $6.5M in a debt funding round, according to a recently regulatory filing by the firm. According to the filing, the funding is part of an ongoing, $14.5M round. No details on the funding have been announced by the firm, which has previously raised funding from Forward Ventures, JAFCO, Novartis Venture Fund, Fidelity Biosciences, MedImmune Ventures, Athenian Venture Partners and MC Life Sciences Ventures (Mitsubishi International Corporation), as well as GlaxoSmithKline. More information »